Literature DB >> 9704725

Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology.

H R Rosen1, G Jatzko, S Repse, S Potrc, H Neudorfer, P Sandbichler, J Zacherl, H Rabl, P Holzberger, P Lisborg, M Czeijka.   

Abstract

PURPOSE: Previous studies have demonstrated a beneficial effect of intraperitoneally applied mitomycin bound to activated carbon particles (M-CH) in preventing intraabdominal recurrence following curative surgery for gastric cancer. The Austrian Working Group for Stomach Cancer, a subgroup of the Austrian Working Group for Surgical Oncology, initiated a multicentric phase III trial to evaluate the safety and efficacy of this treatment regimen. PATIENTS AND METHODS: A total of 91 patients with a radically resected gastric cancer infiltrating the serosal surface were randomly assigned to receive either 50 mg mitomycin bound to a solution of 375 mg carbo adsorbens intraperitoneally before closure of the abdominal wound (n = 46) or served as a surgical control group (n = 45). Postoperative complications and recurrence-free and overall survival were evaluated to analyze the risks and benefits of this treatment.
RESULTS: After a median observation period of 597 days (range, 72 to 1,096), a significantly higher postoperative complication rate was observed in the M-CH group (35%) compared with the control group (16%) (P < .02). In accordance with this finding, the postoperative (60 days) mortality rate was also significantly elevated in the M-CH group (11% v 2% in the control group). Since analysis of overall and recurrence-free survival failed to show any beneficial effect of M-CH therapy, the protocol committee decided to stop further recruitment of patients onto this study.
CONCLUSION: Adjuvant intraperitoneal therapy of gastric cancer by mitomycin bound to activated carbon particles is associated with an increased rate of postoperative complications. However, no benefit for prognosis following radical resection of locally advanced tumors was observed in this multicenter phase III trial.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9704725     DOI: 10.1200/JCO.1998.16.8.2733

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  23 in total

Review 1.  Chemotherapy for upper gastrointestinal tumours.

Authors:  A L Thomas; K O'Byrne; W P Steward
Journal:  Postgrad Med J       Date:  2000-06       Impact factor: 2.401

2.  Guidelines for the management of oesophageal and gastric cancer.

Authors:  W H Allum; S M Griffin; A Watson; D Colin-Jones
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

3.  Meta-analysis of intraperitoneal chemotherapy for gastric cancer.

Authors:  Da-Zhi Xu; You-Qing Zhan; Xiao-Wei Sun; Su-Mei Cao; Qi-Rong Geng
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

4.  Adenocarcinoma of the stomach: a review.

Authors:  James M McLoughlin
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

5.  Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model.

Authors:  Arndt Hribaschek; Roger Kuhn; Matthias Pross; Frank Meyer; Jörg Fahlke; Karsten Ridwelski; Carsten Boltze; Hans Lippert
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

6.  Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer.

Authors:  Sheng-Liu Xue; Hua-Fang Su; Xiao-Qu Hu; Xia Deng; Mei-Long Hu; Cong-Ying Xie
Journal:  Oncol Lett       Date:  2012-09-13       Impact factor: 2.967

Review 7.  Intraperitoneal drug delivery of antineoplastics.

Authors:  M Markman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Hyperthermic intraperitoneal chemotherapy (HIPEC) and neoadjuvant chemotherapy as prophylaxis of peritoneal carcinosis from advanced gastric cancer-effects on overall and disease free survival.

Authors:  Federico Coccolini; Andrea Celotti; Marco Ceresoli; Giulia Montori; Michele Marini; Fausto Catena; Luca Ansaloni
Journal:  J Gastrointest Oncol       Date:  2016-08

Review 9.  Extent of lymphadenectomy and perioperative therapies: two open issues in gastric cancer.

Authors:  Andrea Giuliani; Michelangelo Miccini; Luigi Basso
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 10.  Chemotherapy for gastric cancer.

Authors:  Javier Sastre; Jose Angel Garcia-Saenz; Eduardo Diaz-Rubio
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.